Adolescents and Young Adults Acute Lymohoblastic Leukemia
Conditions
Interventions
Experimental group:On the basis of CCLG-ALL 2018 protocol, the supplementary chemotherapy regimen for the initial chemotherapy intolerance group and the supplementary chemotherapy regimen for the remi
Sponsors
Beijing Childrens Hospital,Capital Medical University
Eligibility
Sex/Gender
All
Age
10 Years to 29 Years
Inclusion criteria
Inclusion criteria: 1.Definitive diagnosis of ALL; 2.Age between 10 and 29 years old; 3.No prior treatment received before diagnosis, excluding single-dose intrathecal injection; 4.Written informed consent obtained from the patients or/and their guardians;
Exclusion criteria
Exclusion criteria: 1.Mature types of lymphocytic leukemia; 2.Patients who are only receiving temporary chemotherapy, radiotherapy, or immunotherapy without committing to systematic treatment according to the protocol; 3.Use of any antitumor therapy within 2 weeks prior to enrollment, except for the single-dose intrathecal injection mentioned above and hydroxyurea or low-dose cytarabine used for treating hyperleukocytosis; 4.Presence of any significant comorbidities or psychiatric conditions that may affect the patient's safety, compliance, ability to give informed consent, participation in the study, follow-up, or interpretation of results;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Event-free survival;Complete remission after the induction therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to achieve MRD negativity after treatment;Time to achieve CR after treatment; | — |
Countries
China
Contacts
Public ContactHuyong Zheng/Yu Jiaoyue
Beijing Childrens Hospital,Capital Medical University
Outcome results
None listed